09AF_Att2_60 Day FRN

09AF_Att2_60 Day FRN.pdf

Evaluation of Pharmacy Syringe Access Linked to HIV Testing for Injection Drug Users in New York City (Pharm-HIV)

09AF_Att2_60 Day FRN

OMB: 0920-0837

Document [pdf]
Download: pdf | pdf
“Evaluation of Pharmacy Syringe Access Linked to HIV
Testing for Injection Drug Users in New York City (PharmHIV)”
Attachment 2
60-day Federal Register Notice

Federal Register / Vol. 73, No. 224 / Wednesday, November 19, 2008 / Notices
FEDERAL MARITIME COMMISSION

FEDERAL RESERVE SYSTEM

Notice of Change to Meeting

Formations of, Acquisitions by, and
Mergers of Bank Holding Companies

Agency Holding the Meeting:
Federal Maritime Commission.
Federal Register Citation of Previous
Announcement: 73 FR 67869.
Previously Announced Time and Date
of the Meeting: 10 a.m. on November 20,
2008.
Change:
1. The addition of Item 2 to the Open
Session of the Meeting: Item 2—FY 2009
Budget Status Report.
For More Information Contact:
Karen V. Gregory, Secretary, (202)
523–5725.
Karen V. Gregory,
Secretary.
[FR Doc. E8–27598 Filed 11–17–08; 4:15 pm]
BILLING CODE 6730–01–P

FEDERAL MARITIME COMMISSION
Ocean Transportation Intermediary
License; Applicants
Notice is hereby given that the
following applicants have filed with the
Federal Maritime Commission an
application for license as a Non-Vessel
Operating Common Carrier and Ocean
Freight Forwarder—Ocean
Transportation Intermediary pursuant to
section 19 of the Shipping Act of 1984
as amended (46 U.S.C. Chapter 409 and
46 CFR 515).
Persons knowing of any reason why
the following applicants should not
receive a license are requested to
contact the Office of Transportation
Intermediaries, Federal Maritime
Commission, Washington, DC 20573.

cprice-sewell on PROD1PC64 with NOTICES

Non-Vessel Operating Common Carrier
and Ocean Freight Forwarder
Transportation Intermediary
Applicants
InterChez Global Services, Inc., 3924
Clock Pointe Trail, Suite 101, Stow,
OH 44224; Officer: Melissa F. Lines,
Vice President, (Qualifying
Individual).
Morrison Express Corporation (USA),
2000 Hughes Way, El Segundo, CA
90248; Officer: Douglas E. Haring,
Vice President, (Qualifying
Individual).
Dated: November 14, 2008.
Karen V. Gregory,
Secretary.
[FR Doc. E8–27499 Filed 11–18–08; 8:45 am]
BILLING CODE 6730–01–P

VerDate Aug<31>2005

15:14 Nov 18, 2008

Jkt 217001

The companies listed in this notice
have applied to the Board for approval,
pursuant to the Bank Holding Company
Act of 1956 (12 U.S.C. 1841 et seq.)
(BHC Act), Regulation Y (12 CFR Part
225), and all other applicable statutes
and regulations to become a bank
holding company and/or to acquire the
assets or the ownership of, control of, or
the power to vote shares of a bank or
bank holding company and all of the
banks and nonbanking companies
owned by the bank holding company,
including the companies listed below.
The applications listed below, as well
as other related filings required by the
Board, are available for immediate
inspection at the Federal Reserve Bank
indicated. The applications also will be
available for inspection at the offices of
the Board of Governors. Interested
persons may express their views in
writing on the standards enumerated in
the BHC Act (12 U.S.C. 1842(c)). If the
proposal also involves the acquisition of
a nonbanking company, the review also
includes whether the acquisition of the
nonbanking company complies with the
standards in section 4 of the BHC Act
(12 U.S.C. 1843). Unless otherwise
noted, nonbanking activities will be
conducted throughout the United States.
Additional information on all bank
holding companies may be obtained
from the National Information Center
website at www.ffiec.gov/nic/.
Unless otherwise noted, comments
regarding each of these applications
must be received at the Reserve Bank
indicated or the offices of the Board of
Governors not later than December 12,
2008.
A. Federal Reserve Bank of Atlanta
(Steve Foley, Vice President) 1000
Peachtree Street, N.E., Atlanta, Georgia
30309:
1. Protective Life Corporation,
Birmingham, Alabama; to become a
bank holding company by acquiring 100
percent of the voting shares of Bonifay
Holding Company, Inc., and its
subsidiary, The Bank of Bonifay, both of
Bonifay, Florida.
B. Federal Reserve Bank of Kansas
City (Todd Offerbacker, Assistant Vice
President) 925 Grand Avenue, Kansas
City, Missouri 64198-0001:
1. Union State Banc Holding
Company, Clay Center, Kansas; to
become a bank holding company by
acquiring 100 percent of the voting
shares of Union State Bank, Clay Center,
Kansas.

PO 00000

Frm 00065

Fmt 4703

Sfmt 4703

69663

C. Federal Reserve Bank of San
Francisco (Tracy Basinger, Director,
Regional and Community Bank Group)
101 Market Street, San Francisco,
California 94105-1579:
1. Marlin Business Services
Corporation., Mount Laurel, New Jersey;
to become a bank holding company by
acquiring 100 percent of the voting
shares of Marlin Business Bank, Salt
Lake City, Utah.
In connection with this application,
Applicant also has applied to engage
indirectly in leasing activities through
Marlin Leasing Corporation, Mount
Laurel, New Jersey, pursuant to
225.28(b)(3) of Regulation Y.
Board of Governors of the Federal Reserve
System, November 14, 2008.
Robert deV. Frierson,
Deputy Secretary of the Board.
[FR Doc. E8–27470 Filed 11–18–08; 8:45 am]
BILLING CODE 6210–01–S

DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[60 Day–09–09AF]

Proposed Data Collections Submitted
for Public Comment and
Recommendations
In compliance with the requirement
of Section 3506(c)(2)(A) of the
Paperwork Reduction Act of 1995 for
opportunity for public comment on
proposed data collection projects, the
Centers for Disease Control and
Prevention (CDC) will publish periodic
summaries of proposed projects. To
request more information on the
proposed projects or to obtain a copy of
the data collection plans and
instruments, call 404–639–5960 or send
comments to Maryam Daneshvar PhD,
CDC Reports Clearance Officer, 1600
Clifton Road, MS–D74, Atlanta, GA
30333 or send an e-mail to
[email protected].
Comments are invited on: (a) Whether
the proposed collection of information
is necessary for the proper performance
of the functions of the agency, including
whether the information shall have
practical utility; (b) the accuracy of the
agency’s estimate of the burden of the
proposed collection of information; (c)
ways to enhance the quality, utility, and
clarity of the information to be
collected; and (d) ways to minimize the
burden of the collection of information
on respondents, including through the
use of automated collection techniques
or other forms of information

E:\FR\FM\19NON1.SGM

19NON1

69664

Federal Register / Vol. 73, No. 224 / Wednesday, November 19, 2008 / Notices

technology. Written comments should
be received within 60 days of this
notice.
Proposed Project
‘‘Evaluation of Pharmacy Syringe
Access Linked to HIV Testing for
Injection Drug Users in New York City
(Pharm-HIV)’’—New—National Center
for HIV/AIDS, Viral Hepatitis, STD, and
TB Prevention (NCHHSTP). Centers for
Disease Control and Prevention (CDC).
Background and Brief Description
HIV continues to be one of the leading
causes of illness and death in the US,
especially among black and Hispanic
communities. For injection drug users
(IDU), who are at high risk of acquiring
HIV infection, HIV testing may not be
readily accessible. In 2001, the New
York State Legislature established an
Expanded Syringe Access
Demonstration Program (ESAP) in New
York City which made syringes
available through participating

City; ten of which will test a model that
refers injection-drug-using syringe
customers for HIV testing to local HIV
testing sites. Two ESAP pharmacies will
evaluate the feasibility of offering and
performing HIV counseling and testing
in the pharmacy for injection-drug-using
syringe customers.
Two types of respondents will
provide the individual-level data; fortyeight adult (age ≥18 yrs) pharmacy staff
members will be surveyed to learn about
pharmacy staff attitudes and behaviors
regarding HIV testing and referral. The
other respondent group will be 442
adult (age ≥18 yrs) injection-drug-using
syringe customers who will complete a
brief quantitative interview after HIV
referral or HIV testing is offered to them.
HIV-seropositive injection-drug-using
syringe customers identified during HIV
testing will be immediately linked to
social and medical services. There is no
cost to respondents other than their
time.

pharmacies for injection drug users.
ESAP thus helped to reduce the burden
of HIV by increasing access to sterile
syringe sources. The ESAP allows for
regular contact between pharmacists
and their injection-drug-using syringe
customers, thus paving the way for
pharmacies to act as access points to
health and social services among IDU
customers. The expansion of pharmacy
services to include referrals for
injection-drug-using syringe customers
is based on the successes of ESAP,
which provides many services beyond
syringe exchange.
This project involves two kinds of
studies: testing service models at
pharmacies and, interviewing
individuals regarding the availability of
syringes through pharmacies. For testing
service models CDC will collaborate
with the New York Academy of
Medicine (NYAM) to implement this
project for a period of three years.
The NYAM will identify 12 ESAP
pharmacies in East Harlem, New York

ESTIMATE OF ANNUALIZED BURDEN TABLE
Number of
respondents

Types of data collection

Pharmacy telephone screening and enrollment form ......................................
Pharmacy staff surveys—baseline, every six months x 3, and at end of
study. ............................................................................................................
Pharmacy staff brief surveys—monthly except when 6 monthly surveys are
completed. ....................................................................................................
Pharmacy daily syringe sales log ....................................................................
Injection-drug-using syringe customer surveys ...............................................
Total ..........................................................................................................

Dated: November 7, 2008.
Maryam I. Daneshvar,
Acting Reports Clearance Officer, Centers for
Disease Control and Prevention.
[FR Doc. E8–27448 Filed 11–18–08; 8:45 am]
BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND
HUMAN SERVICES

cprice-sewell on PROD1PC64 with NOTICES

Centers for Disease Control and
Prevention
Subcommittee for Dose
Reconstruction Reviews (SDRR),
Advisory Board on Radiation and
Worker Health (ABRWH), National
Institute for Occupational Safety and
Health (NIOSH)
In accordance with section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC),

VerDate Aug<31>2005

15:14 Nov 18, 2008

Jkt 217001

1

10/60

4

48

5

20/60

80

12
12
442

19
600
1

10/60
5/60
30/60

38
600
221

........................

........................

........................

943

Time and Date: 9:30 a.m.–5 p.m.,
December 8, 2008.
Place: Cincinnati Airport Marriott, 2395
Progress Drive, Hebron, Kentucky 41018.
Telephone (859) 334–4611, Fax (859) 334–
4619.
Status: Open to the public, but without a
public comment period. To access by
conference call dial the following
information 1(866) 659–0537, Participant
Pass Code 9933701.
Background: The Advisory Board was
established under the Energy Employees
Occupational Illness Compensation Program
Act of 2000 to advise the President on a
variety of policy and technical functions
required to implement and effectively
manage the new compensation program. Key
functions of the Advisory Board include
providing advice on the development of
probability of causation guidelines that have
been promulgated by the Department of
Health and Human Services (HHS) as a final
rule; advice on methods of dose
reconstruction which have also been
promulgated by HHS as a final rule; advice

Frm 00066

Fmt 4703

Total burden
(in hours)

24

announces the following meeting for the
aforementioned subcommittee:

PO 00000

Average
burden per
response
(in hours)

Number of
responses per
respondent

Sfmt 4703

on the scientific validity and quality of dose
estimation and reconstruction efforts being
performed for purposes of the compensation
program; and advice on petitions to add
classes of workers to the Special Exposure
Cohort (SEC).
In December 2000, the President delegated
responsibility for funding, staffing, and
operating the Advisory Board to HHS, which
subsequently delegated this authority to CDC.
NIOSH implements this responsibility for
CDC. The charter was issued on August 3,
2001, renewed at appropriate intervals, and
will expire on August 3, 2009.
Purpose: The Advisory Board is charged
with (a) Providing advice to the Secretary,
HHS, on the development of guidelines
under Executive Order 13179; (b) providing
advice to the Secretary, HHS, on the
scientific validity and quality of dose
reconstruction efforts performed for this
program; and (c) upon request by the
Secretary, HHS, advising the Secretary on
whether there is a class of employees at any
Department of Energy facility who were
exposed to radiation but for whom it is not
feasible to estimate their radiation dose, and
on whether there is reasonable likelihood

E:\FR\FM\19NON1.SGM

19NON1


File Typeapplication/pdf
File Title“Evaluation of Pharmacy Syringe Access Linked to HIV Testing for Injection Drug Users in New York City (Pharm-HIV)”
AuthorChristine Dao
File Modified2009-03-06
File Created2009-03-06

© 2024 OMB.report | Privacy Policy